| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8470359 | TOLMAR THERAP | Sustained release polymer |
Oct, 2023
(16 days from now) | |
Eligard Kit is owned by Tolmar Therap.
Eligard Kit contains Leuprolide Acetate.
Eligard Kit has a total of 1 drug patent out of which 0 drug patents have expired.
Eligard Kit was authorised for market use on 24 July, 2002.
Eligard Kit is available in powder;subcutaneous dosage forms.
Eligard Kit can be used as method of treating cancer.
The generics of Eligard Kit are possible to be released after 15 October, 2023.
Drugs and Companies using LEUPROLIDE ACETATE ingredient
Market Authorisation Date: 24 July, 2002
Treatment: Method of treating cancer
Dosage: POWDER;SUBCUTANEOUS
ELIGARD KIT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic